Montmorillonite related concept stocks exploded! Many stocks such as Kangzhi Pharmaceutical had a 20CM price limit

【Pharmaceutical Network Pharmaceutical Stock Market】Since the beginning of 2023, the drug "montmorillonite scatter" used by gastroenterology to treat diarrhea has set off a rush to buy in the market, and related concept stocks have ushered in a big outbreak
.
As of the close of trading on January 3, the montmorillonite scattered index rose by more than 10% on the day, of which 5 stocks were up and down, namely Kangzhi Pharmaceutical, Tongyuan Pharmaceutical, Yiming Pharmaceutical, Fangsheng Pharmaceutical, China Resources Shuanghe, and many head stocks even had a 20CM price limit
.
As of the close on January 3, Kangzhi Pharmaceutical closed at 7.
46 yuan, up 19.
94%, up the limit, with a turnover rate of 9.
54%, a volume of 415,400 lots, and a turnover of 309 million yuan
.
On the news, Kangzhi Pharmaceutical recently said on the investor interactive platform that the company has produced and sold montmorillonite, and the product has passed the consistency evaluation
of the quality and efficacy of generic drugs in early 2021.
At present, the company works overtime production through external recruitment, transfer of employees from other bases, adjustment of shifts, etc.
, to ensure the supply of
products.
As of the close on January 3, Tongyuan Pharmaceutical closed at 8.
12 yuan, up 19.
94%, up the limit, with a turnover rate of 14.
22%, a volume of 318,700 lots, and a turnover of 256 million yuan
.
It is understood that the main business of Tongyuan Pharmaceutical is the research and development, production, sales of medicine and health food, as well as medical and health services, business services and commercial businesses such as medical diagnosis, gene preservation and pregnancy environment testing
.
On August 26 this year, the company disclosed in the annual report that the company's products have montmorillonite powder, and the company's product montmorillonite powder passed the consistency evaluation
.
In addition, in February, its holding subsidiary was entrusted with the production of MOLNUPIVIR generic drug entities
.
As of the close of trading on January 3, Yiming Pharmaceutical's share price rose by 10.
01%, and the closing price was 11.
21 yuan
.
Yiming Pharmaceutical is mainly engaged in the research and development, production and sales
of chemical drugs (APIs and preparations) and proprietary Chinese medicines.
The main drugs produced and sold by the company are divided into treatment areas and characteristics, which can be classified as diabetes drugs, coronary heart disease drugs, opioid receptor antagonist drugs, breast hyperplasia disease drugs, anti-inflammatory and anti-rheumatic drugs
.
It is understood that the company also disclosed during the reporting period that it had obtained the "Drug Supplement Application Approval" for the chemical drug "montmorillonite powder", and it was the first batch of montmorillonite bulk products
in China that passed the consistency evaluation of generic drugs.
As of the close of trading on January 3, Fangsheng Pharmaceutical's share price rose 9.
99%, closing at 8.
81 yuan
.
The analysis believes that the reasons for Fangsheng Pharmaceutical's price limit include montmorillonite, traditional Chinese medicine and ophthalmic medicine
.
The company is mainly engaged in the research and development, production and sales of cardiovascular and cerebrovascular proprietary medicines, orthopedic drugs, pediatric drugs, gynecological drugs, anti-infective drugs and other drugs; According to Fangsheng Pharmaceutical's 2021 annual report, in January 2021, the company received the "Drug Supplement Application Approval Notice" issued by the State Food and Drug Administration on montmorillonite powder, confirming that the drug passed the consistency evaluation of the quality and efficacy of generic drugs, and the company sold 54.
9048 million bags
of montmorillonite powder that year.
In addition, the company holds 65% of the shares of Jida Gene, and its main research project is recombinant human keratinocytes growth factor-2 eye drops, which are mainly used for the treatment of corneal abrasions, mild to moderate chemical burns, corneal surgery and postoperative poor healing and corneal epithelial defects caused by dry eyes, and are currently undergoing clinical research
.
As of the close on January 3, China Resources Shuanghe closed at 19.
68 yuan, up 10.
01%, up the limit, with a turnover rate of 5.
51%, a volume of 564,100 lots, and a turnover of 1.
092 billion yuan
.
CR Shuanghe's main business is chronic disease business, specialty business and infusion business
.
In 2020, the company had 4 products that passed the consistency evaluation, including montmorillonite
.
In addition, the company announced on August 31 this year that Real Bio has obtained the "Drug Production License" B certificate issued by the Henan Provincial Drug Administration, with Real Bio as the marketing authorization holder, and China Resources Shuanghe as the entrusted manufacturer entrusted with the production of azvudine tablets
.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.